Kinase Inhibitors

Kinase Inhibitor

Cytochrome P450 2C9 Inhibitors

Breast Cancer Resistance Protein Inhibitors

UGT1A1 Inhibitors

UGT1A9 Inhibitors

Carcinoma, Hepatocellular

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

<section class="Section" data-sectioncode="34089-3"><a name="ID_291dfd3b-a1c9-424d-8888-61fc1a2d2dd8"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">STIVARGA (regorafenib) is a multikinase inhibitor with the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:</p><div class="Figure"><a name="id-1188748292"></a><img alt="Description: Chemical Structure" src="image-02.jpg"/></div><p>Regorafenib is a monohydrate and it has a molecular formula C<span class="Sub">21</span>H<span class="Sub">15</span>ClF<span class="Sub">4</span>N<span class="Sub">4</span>O<span class="Sub">3</span> • H<span class="Sub">2</span>O and a molecular weight of 500.83. Regorafenib is practically insoluble in water, slightly soluble in acetonitrile, methanol, ethanol, and ethyl acetate and sparingly soluble in acetone.</p><p>STIVARGA tablets for oral administration are formulated as light pink, oval-shaped tablets debossed with "BAYER" on one side and "40" on the other. Each tablet contains 40 mg of regorafenib in the anhydrous state, which corresponds to 41.49 mg of regorafenib monohydrate, and the following inactive ingredients: cellulose microcrystalline, croscarmellose sodium, magnesium stearate, povidone, and colloidal silicon dioxide. The film-coating contains the following inactive ingredients: ferric oxide red, ferric oxide yellow, lecithin (soy), polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide.</p></section>

Stivarga

regorafenib

regorafenib 40 MG Oral Tablet

regorafenib 40 MG Oral Tablet [Stivarga]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program

Other HCP Resources - Access

Other HCP Resources

Instructions For Use: mCRC 

Instructions For Use: GIST

Instructions For Use: HCC

Other HCP Resources: Video Library